By application of protein engineering methods (data not shown) we identified a variant of IL-18, attenuated ~10,000-fold, which, when fused to an αPD-1 antibody, enhances anti-tumor activity and preserves/expands TpEX cells in the tumor microenvironment while maintaining full checkpoint inhibition with minimal systemic activity. This evidence concerns the gene IL18 and neoplasm.